ADVOCATE. CONNECT. INNOVATE.

CLSA Wire

Report: Anticipated Effects of International Reference Pricing on California’s Biopharmaceutical Innovation Ecosystem

The California Life Sciences Association (CLSA)—the statewide public policy organization representing California’s life sciences innovators, including medical device, diagnostic, biotechnology and pharmaceutical companies, research universities and private, non-profit institutes, and venture capital firms—commissioned a study from international health economics firm, Vital Transformation, to examine the impact that utilizing international reference pricing in Medicare Part D (as proposed in H.R. 3, the Lower Drug Costs Now Act of 2019) would have on the world-class innovative biotechnology sector in California. Below is a summary of our analysis.

DOWNLOAD REPORT